Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
With luck, Santa Clarita?s MannKind Corporation hopes to have FDA approval by April of next year of its innovative diabetes treatment ? Afrezza.
First conceived in 2011, and funded to a great extent by serial biomed and high tech entrepreneur Alfred Mann, MannKind is a publically traded company whose shares of stock have risen steadily as the company approached the end of its final clinical trials on June 17.
Treating diabetes with insulin, a very potent drug, is tricky, said Matthew Pfeffer, corporate vice president and CFO of the MannKind Corporation.
Using insulin requires a delicate balance of finger-pricking tests, measured doses and timing ? making it hard for lay patients to treat themselves adequately. As a result, doctors will underprescribe insulin to patients to create a safety margin, Pfeffer said.
http://www.signalscv.com/section/434/article/101398/
I'd much rather be making my own judgments on insulin doses than asking my GP what I should be taking! 🙄 (Yes, I know they probably don't mean people on basal/bolus! 😉)
First conceived in 2011, and funded to a great extent by serial biomed and high tech entrepreneur Alfred Mann, MannKind is a publically traded company whose shares of stock have risen steadily as the company approached the end of its final clinical trials on June 17.
Treating diabetes with insulin, a very potent drug, is tricky, said Matthew Pfeffer, corporate vice president and CFO of the MannKind Corporation.
Using insulin requires a delicate balance of finger-pricking tests, measured doses and timing ? making it hard for lay patients to treat themselves adequately. As a result, doctors will underprescribe insulin to patients to create a safety margin, Pfeffer said.
http://www.signalscv.com/section/434/article/101398/
I'd much rather be making my own judgments on insulin doses than asking my GP what I should be taking! 🙄 (Yes, I know they probably don't mean people on basal/bolus! 😉)